Bial R&d Investments, S.a.

This study tests an experimental drug (BIA 28-6156) in 237 people with Parkinson's disease who have a specific change in the GBA1 gene. The goal is to see if the drug can delay worsening of motor symptoms over 78 weeks compared to a placebo. Participants are randomly assigned to …